Gilead Sciences has selected Cognizant for an expanded partnership due to its proven expertise in AI, digital transformation, and IT infrastructure management.
The collaboration, which has been in place for over a decade, has supported Gilead’s global IT platforms, applications, and advanced analytics, enabling the company to focus on its mission of discovering and delivering critical medicines for cancer, HIV, and other life-threatening diseases.
By extending this relationship, Gilead aims to enhance efficiency, reduce costs, and accelerate innovation through Cognizant’s advanced technology solutions.
One of the key reasons for this expansion is Cognizant’s capability in leveraging machine learning and generative AI within an agentic framework to improve multiple areas of Gilead’s business, including customer service, employee interactions, and business value management.
By deploying these AI-driven solutions, Cognizant seeks to optimize Gilead’s financial framework while enhancing overall productivity. Gilead expects to extract greater value from the partnership by implementing cutting-edge technologies that streamline operations, improve decision-making, and drive meaningful business outcomes.
Cognizant’s Neuro AI generative AI platform is another pivotal factor in this partnership. The platform is expected to accelerate value creation by optimizing IT and business processes, ultimately leading to substantial cost savings. These savings can be reinvested into Gilead’s core life sciences business, ensuring that more resources are directed toward advancing critical medical research and drug development. Additionally, Cognizant plans to transform the user experience of IT services at Gilead by deploying customized generative AI solutions that enhance operational efficiency and user engagement.
Joydeep Ganguly, Gilead’s SVP & Head of Corporate Operations and Interim CIO, says Cognizant’s expertise is instrumental in accelerating the company’s digital transformation while simultaneously achieving a new level of cost leadership. This partnership is expected to introduce innovative changes to Gilead’s business, enhancing operational performance and unlocking new possibilities for growth.
Cognizant executives have also underscored the significance of this agreement in transforming user engagement, boosting productivity, and increasing cost savings for Gilead. The partnership will enable Gilead to focus more on its core mission of preventing and treating life-threatening illnesses, while Cognizant takes charge of streamlining and enhancing its technological landscape.
Furthermore, Cognizant aims to provide value acceleration through its life sciences domain expertise, utilizing premier managed services frameworks and advanced automation tools to drive operational efficiencies.
By selecting Cognizant, Gilead is ensuring that it remains at the forefront of technological innovation, maximizing its potential through AI-driven solutions and cost-effective IT strategies. This expanded agreement solidifies Cognizant’s role as a strategic partner in Gilead’s journey toward greater efficiency, productivity, and impact in the global healthcare sector.
